ARRB1 and neoplasm: In addition, correlations between ARRB1 and predictors of immune checkpoint inhibitor (ICI) efficacy (tumor mutation burden [TMB], microsatellite instability [MSI], and Programmed cell death-ligand 1 [PD-L1]).